Literature DB >> 24846683

Detection of ALK rearrangement in an octogenarian patient with pleomorphic carcinoma of the lung.

Riichiroh Maruyama1, Fujio Matsumura2, Yuji Shibata2, Hiroshi Takahashi3, Hiroko Okabayashi3, Sachiyo Kosai3, Izumi Honda3, Susumu Ohkawara4, Mineharu Sugimoto3.   

Abstract

We herein present a rare case of ALK-positive pulmonary pleomorphic carcinoma in an octogenarian patient. A computed tomography scan of the thorax indicated a pulmonary nodule in the right upper lobe of an asymptomatic 87-year-old female. The surgical resection revealed that the disease was pleomorphic carcinoma with pathological T2aN0M0, stage IB. EML4-ALK was evaluated using immunohistochemistry and fluorescence in situ hybridization, and EGFR mutations were analyzed using the Cycleave method. While there were no EGFR mutations detected, she was positive for the ALK rearrangement. This is the first report of ALK rearrangement in an octogenarian patient with pleomorphic carcinoma of the lung.

Entities:  

Keywords:  Anaplastic lymphoma kinase; Fluorescence in situ hybridization; Gene rearrangement; Octogenarian; Pleomorphic carcinoma

Mesh:

Substances:

Year:  2014        PMID: 24846683     DOI: 10.1007/s11748-014-0428-4

Source DB:  PubMed          Journal:  Gen Thorac Cardiovasc Surg        ISSN: 1863-6705


  5 in total

1.  Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

Authors:  Eunice L Kwak; Yung-Jue Bang; D Ross Camidge; Alice T Shaw; Benjamin Solomon; Robert G Maki; Sai-Hong I Ou; Bruce J Dezube; Pasi A Jänne; Daniel B Costa; Marileila Varella-Garcia; Woo-Ho Kim; Thomas J Lynch; Panos Fidias; Hannah Stubbs; Jeffrey A Engelman; Lecia V Sequist; WeiWei Tan; Leena Gandhi; Mari Mino-Kenudson; Greg C Wei; S Martin Shreeve; Mark J Ratain; Jeffrey Settleman; James G Christensen; Daniel A Haber; Keith Wilner; Ravi Salgia; Geoffrey I Shapiro; Jeffrey W Clark; A John Iafrate
Journal:  N Engl J Med       Date:  2010-10-28       Impact factor: 91.245

2.  Multiparametric molecular characterization of pulmonary sarcomatoid carcinoma reveals a nonrandom amplification of anaplastic lymphoma kinase (ALK) gene.

Authors:  Giuseppe Pelosi; Patrizia Gasparini; Alberto Cavazza; Giulio Rossi; Paolo Graziano; Mattia Barbareschi; Federica Perrone; Massimo Barberis; Masayuki Takagi; Toshiaki Kunimura; Tetsuya Yamada; Yukio Nakatani; Ugo Pastorino; Paolo Scanagatta; Gabriella Sozzi; Marina Garassino; Filippo De Braud; Mauro Papotti
Journal:  Lung Cancer       Date:  2012-06-16       Impact factor: 5.705

3.  A prospective PCR-based screening for the EML4-ALK oncogene in non-small cell lung cancer.

Authors:  Manabu Soda; Kazutoshi Isobe; Akira Inoue; Makoto Maemondo; Satoshi Oizumi; Yuka Fujita; Akihiko Gemma; Yoshihiro Yamashita; Toshihide Ueno; Kengo Takeuchi; Young Lim Choi; Hitoshi Miyazawa; Tomoaki Tanaka; Koichi Hagiwara; Hiroyuki Mano
Journal:  Clin Cancer Res       Date:  2012-08-20       Impact factor: 12.531

4.  Favorable clinical outcomes of pemetrexed treatment in anaplastic lymphoma kinase positive non-small-cell lung cancer.

Authors:  Ha Yeon Lee; Hee Kyung Ahn; Ji Yun Jeong; Mi Jung Kwon; Jung-Ho Han; Jong-Mu Sun; Jin Seok Ahn; Keunchil Park; Yoon-La Choi; Myung-Ju Ahn
Journal:  Lung Cancer       Date:  2012-10-25       Impact factor: 5.705

5.  Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

Authors:  Alice T Shaw; Dong-Wan Kim; Kazuhiko Nakagawa; Takashi Seto; Lucio Crinó; Myung-Ju Ahn; Tommaso De Pas; Benjamin Besse; Benjamin J Solomon; Fiona Blackhall; Yi-Long Wu; Michael Thomas; Kenneth J O'Byrne; Denis Moro-Sibilot; D Ross Camidge; Tony Mok; Vera Hirsh; Gregory J Riely; Shrividya Iyer; Vanessa Tassell; Anna Polli; Keith D Wilner; Pasi A Jänne
Journal:  N Engl J Med       Date:  2013-06-01       Impact factor: 91.245

  5 in total
  2 in total

1.  Pulmonary Sarcomatoid Carcinoma with ALK Rearrangement: Frequency, Clinical-Pathologic Characteristics, and Response to ALK Inhibitor.

Authors:  Xinru Chen; Yu Zhang; Jiabin Lu; Chunwei Xu; Jianzhong Liang; Fang Wang; Wenyong Sun; Sangao Fang; Jingping Yuan; Huijuan Wang; Hui Wang; Xuewen Liu; Likun Chen
Journal:  Transl Oncol       Date:  2017-01-10       Impact factor: 4.243

2.  Anaplastic lymphoma kinase (ALK)-rearranged pulmonary pleomorphic carcinoma successfully treated with crizotinib.

Authors:  Liping Lin; Fuxi Huang; Fang Chen; Yan He; Jiazhu Hu; Xiaolong Cao
Journal:  J Int Med Res       Date:  2018-01-08       Impact factor: 1.671

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.